HK1244704A1 - 一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物 - Google Patents

一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物

Info

Publication number
HK1244704A1
HK1244704A1 HK18104329.4A HK18104329A HK1244704A1 HK 1244704 A1 HK1244704 A1 HK 1244704A1 HK 18104329 A HK18104329 A HK 18104329A HK 1244704 A1 HK1244704 A1 HK 1244704A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
composition containing
kinase inhibitor
Prior art date
Application number
HK18104329.4A
Other languages
English (en)
Inventor
盧韵
陳昊
潘曉晨
Original Assignee
江蘇恒瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇恒瑞醫藥股份有限公司 filed Critical 江蘇恒瑞醫藥股份有限公司
Publication of HK1244704A1 publication Critical patent/HK1244704A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18104329.4A 2016-02-19 2018-03-29 一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物 HK1244704A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610094168 2016-02-19
PCT/CN2017/073869 WO2017140254A1 (zh) 2016-02-19 2017-02-17 一种含有jak激酶抑制剂或其可药用盐的药物组合物

Publications (1)

Publication Number Publication Date
HK1244704A1 true HK1244704A1 (zh) 2018-08-17

Family

ID=59624719

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104329.4A HK1244704A1 (zh) 2016-02-19 2018-03-29 一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物

Country Status (13)

Country Link
US (1) US10786507B2 (zh)
EP (1) EP3417861B1 (zh)
JP (1) JP6875407B2 (zh)
KR (1) KR20180109992A (zh)
CN (1) CN107530348B (zh)
AU (1) AU2017220971A1 (zh)
BR (1) BR112018015369A2 (zh)
CA (1) CA3014090A1 (zh)
HK (1) HK1244704A1 (zh)
MX (1) MX2018009741A (zh)
RU (1) RU2744432C2 (zh)
TW (1) TWI745349B (zh)
WO (1) WO2017140254A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563099B (zh) 2016-08-16 2023-02-03 百济神州有限公司 一种化合物的晶型、其制备和用途
TW201827436A (zh) * 2017-01-20 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220249491A1 (en) * 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
US20230042525A1 (en) * 2019-12-23 2023-02-09 Jiangsu Hengrui Medicine Co., Ltd. Jak kinase inhibitor pharmaceutical composition
MX2022006873A (es) * 2019-12-31 2022-08-18 Pfizer R&D Uk Ltd Formulaciones de capsulas y tabletas de liberacion inmediata estables de 1-((2s,5r)-5-((7h-pirrolo[2,3-d]pirimidin-4-il)amino)- 2-metilpiperidin-1-il)prop-2-en-1-ona.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021318201A1 (en) 2020-07-28 2023-02-02 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
KR20230142449A (ko) 2020-11-17 2023-10-11 아큐티스 바이오테라퓨틱스, 인크. 심부 진피 약물 전달을 위한 조성물 및 방법
TW202227452A (zh) * 2020-12-04 2022-07-16 大陸商廣州費米子科技有限責任公司 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途
CN113813228B (zh) * 2021-10-11 2023-04-18 北京鑫开元医药科技有限公司 一种具有jak激酶抑制活性的注射液及其制备方法和用途
WO2024165036A1 (zh) * 2023-02-07 2024-08-15 瑞石生物医药有限公司 一种局部给药的药物组合物、其制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
ES2655074T3 (es) 2013-06-07 2018-02-16 Jiangsu Hengrui Medicine Co. Ltd. Bisulfato de inhibidor de quinasa Janus (JAK) y procedimiento de preparación del mismo
CN105566327A (zh) 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
DK3216790T3 (da) 2014-11-05 2019-11-25 Jiangsu Hengrui Medicine Co Krystallinsk form af jak-kinasehæmmer-bisulfat og en fremgangsmåde til fremstilling deraf

Also Published As

Publication number Publication date
JP2019505525A (ja) 2019-02-28
US10786507B2 (en) 2020-09-29
RU2018129775A3 (zh) 2020-05-25
EP3417861B1 (en) 2020-09-23
EP3417861A1 (en) 2018-12-26
RU2744432C2 (ru) 2021-03-09
CA3014090A1 (en) 2017-08-24
TWI745349B (zh) 2021-11-11
TW201729812A (zh) 2017-09-01
WO2017140254A1 (zh) 2017-08-24
EP3417861A4 (en) 2019-09-18
KR20180109992A (ko) 2018-10-08
CN107530348A (zh) 2018-01-02
US20190030033A1 (en) 2019-01-31
CN107530348B (zh) 2020-10-20
AU2017220971A1 (en) 2018-08-02
MX2018009741A (es) 2018-11-09
BR112018015369A2 (zh) 2018-12-18
RU2018129775A (ru) 2020-03-19
JP6875407B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
HK1244704A1 (zh) 一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物
IL265360A (en) Pharmaceutical composition
IL265260B (en) pharmaceutical preparations
IL262654A (en) Pharmacy preparation
IL264593A (en) Medicinal preparations containing akt protein kinase inhibitors
IL265349A (en) Pharmaceutical composition
IL252901B (en) Pharmaceutical preparations of tropomyosin-related kinase (trk) inhibitors
GB201819957D0 (en) Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same
HK1255313A1 (zh) 含有培美曲塞或其藥學上可接受的鹽的穩定藥物組合物
IL256339B (en) A derivative of pyrazole or its pharmacy salt
IL304109A (en) Pharmaceutical preparations containing spinamide
IL263040A (en) Pharmaceutical composition comprising eteplirsen
ZA201807125B (en) Pharmaceutical composition of dapagliflozin
GB201615917D0 (en) Pharmaceutical composition
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
PL3454838T3 (pl) Kompozycja farmaceutyczna
HK1243351A1 (zh) 一種含有吡啶並嘧啶類衍生物或其可藥用鹽的藥物組合物
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
HK1243358B (zh) 一種含有喹啉衍生物或其鹽的藥物組合物
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof